Sir,

Drug-induced liver injury (DILI) is a well-recognized complication of several drugs; the diagnosis is often one of exclusion and is associated with poor prognosis (60%--80% mortality without definite treatment with orthotopic liver transplantation).\[[@ref1]\] Extensive hepatic necrosis, coagulopathy, impaired liver synthetic function, and hepatic encephalopathy define acute liver failure.\[[@ref2]\] Depending on disease severity, it may progress to peripheral vasodilation, systemic inflammatory response syndrome, and ultimately multiple organ dysfunction.\[[@ref2]\]

We present the case of a 36-year-old female with medical history remarkable only for menorrhagia who underwent a robot-assisted total abdominal hysterectomy and bilateral salpingoophorectomy. Her social history was unremarkable; *she denied taking any preoperative medications and reported a previous mild documented allergy to morphine in the past (rash)*. She had prior surgical procedures with postoperative nausea and vomiting as the only documented anesthetic-related side effects. The procedure was performed under general anesthesia maintained with desflurane and oxygen. The patient was hemodynamically stable throughout the case and had an uneventful emergence and extubation.

On postoperative day (POD) \#3, she was re-admitted for persistent nausea and vomiting associated to right upper abdominal pain, which intensified on POD\#5. Physical examination and laboratory analyses (including liver function tests) and abdominal ultrasound were within normal limits. She was started on broad-spectrum antibiotic therapy for suspected pneumonia. Over the course of the next days, the patient status deteriorated in a stepwise fashion, requiring mechanical ventilation for respiratory failure. New-onset hepatosplenomegaly with impaired liver function tests and coagulopathy onset by POD\#11. She was started on renal replacement therapy for acute kidney injury and signs of multiorgan failure by POD\#12, and finally she expired on POD\#19. Autoimmune, microbiologic, and toxic panel failed to reveal any potential etiology. Autopsy findings described necrosis of zones 2 and 3, compromising approximately 70%--75% of the liver parenchyma, without the presence of viral inclusions or microabscesses with no signs of fibrosis. Overall findings were more probably associated to a toxin/drug, according to the pathology report.

Acute Liver Failure (ALF) etiology encompasses a variety of toxic, viral, metabolic and vascular insults as well as DILI, which may manifest especially in perioperative patients who receive multiple medications with hepatotoxic potential.\[[@ref1][@ref2]\] The timeline for the clinical presentation of ALF is classified as hyperacute (\<7 days), acute (7--28 days), or subacute (\>28 days to \< 12 weeks).\[[@ref3]\] DILI secondary to modern volatile anesthetics follow a similar pathophysiology to halothane hepatitis: trifluoroacetyl acid (TFA) antibodies and autoantibodies against CYP2E1.\[[@ref4]\]

On further analysis of the case and based on the clinical factors analyzed, the likelihood of possible volatile-induced ALF is high (based on the suspicion of drug-induced liver injury with negative exposure or autoimmune panel and suggestive liver biopsy features). *Unfortunately, due to the patient\'s impending clinical deterioration, the goal* standard test (antibodies reacting with liver microsomal TFA-proteins in serum)\[[@ref5]\] could not be performed.

*In summary, the management of ALF is extremely challenging*. Contemplation of definitive therapy with orthotopic liver *transplantation should be considered in certain patients*, especially when no clinical improvement with conventional medical management is foreseen.
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